Related Experiment Video
Updated: May 15, 2026

Visualizing the Interrenal Steroidogenic Tissue and Its Vascular Microenvironment in Zebrafish
Published on: December 21, 2016
Clinical and molecular spectrum of patients with 17β-hydroxysteroid dehydrogenase type 3 (17-β-HSD3) deficiency
Carla Cristina Telles de Sousa Castro1, Guilherme Guaragna-Filho, Flavia Leme Calais
1Departamento de Pediatria, Faculdade de Ciências Médicas, Universidade Estadual de Campinas, Campinas, SP, Brazil.
Abstract:
The enzyme 17β-hydroxysteroid dehydrogenase type 3 (17-β-HSD3) catalyzes the conversion of androstenedione to testosterone in the testes, and its deficiency is a rare disorder of sex development in 46,XY individuals. It can lead to a wide range of phenotypic features, with variable hormonal profiles. We report four patients with the 46,XY karyotype and 17-β-HSD3 deficiency, showing different degrees of genital ambiguity, increased androstenedione and decreased testosterone levels, and testosterone to androstenedione ratio < 0.8. In three of the patients, diagnosis was only determined due to the presence of signs of virilization at puberty. All patients had been raised as females, and female gender identity was maintained in all of them. Compound heterozygosis for c.277+2T>G novel mutation, and c.277+4A>T mutation, both located within the intron 3 splice donor site of the HSD17B3 gene, were identified in case 3. In addition, homozygosis for the missense p.Ala203Val, p.Gly289Ser, p.Arg80Gln mutations were found upon HSD17B3 gene sequencing in cases 1, 2, and 4, respectively.
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Type I Diabetes III: Clinical Manifestations
Pedigree Analysis
Hypertension III: Clinical Manifestations and Diagnostic Studies
Coronary Artery Disease III: Clinical Manifestations
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

